Top Gum Industries Ltd.

Investor Presentation • May 22, 2024

LEGAL DISCLAIMER

The information included under this presentation (the "Presentation") is for informational purposes only and does not constitute or form any part of any offer to purchase securities and/or an invitation to make offers for their purchase or solicitation of any of the above regarding any securities of Top Gum Industries Ltd. (the "Company") and should not be regarded as a recommendation or an opinion. Any such offer or sale will be made on the basis of a prospectus published by the Company after receiving a permit from the Securities Authority and approval from the Tel Aviv Stock Exchange (hereinafter, respectively: "Securities Authority" and "the Stock Exchange").

This presentation does not purport to encompass or contain any information that may be relevant for the purpose of making any decision regarding an investment in the Company's securities and generally. This presentation does not replace independent data collection and analysis, it should be bear in mind that past data does not necessarily indicate future performance. The presentation includes data and statistics and other publications published by third parties, the content of which has not been independently verified by the Company. The presentation was made, for a convenient and concise presentation, and it does not exhaust the full data about the company and its activities and does

not replace the need to perform a full due diligence. The information contained in this presentation is incomplete and all that is stated in it is subject to a full due diligence and is not a substitute for reviewing reports published by the Company to the public and especially in the draft prospectus or final company prospectus, supplementary prospectus and shelf prospectus. The information under this Presentation is not a substitute for public Information and in the event of any conflict between the content of this presentation and the content of any public Information, the content of the Public Information shall prevail. The information in this Presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be made on the fairness, accuracy, completeness or correctness of the information or opinions contained herein. No legally binding obligations may be created, implied, or inferred from this Presentation. Various statements in this presentation include information which derives from forecasts, estimates, assessments, and other information pertaining to future events and/or matters, the materialization of which is uncertain and beyond the Company's control, and which constitute "forwardlooking information", as defined under the Israeli Securities Law, 1968. Forward-looking statements include descriptions regarding the intent,

belief, or current expectations of the Company and are not guaranteeing future results, performance, or achievements and are based on current expectations, estimations, and assumptions, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performances, or achievements of the Company may differ materially from what is or may be expressed or implied in this presentation due to a variety of factors, many of which are beyond the Company's control, including, without limitation, certain risk factors. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events, or otherwise. Certain information and factual statements (including relating to markets or trends) contained herein are based on or derived from publicly available documents or independent third-party sources, and therefore the accuracy of such information and the assumptions on which such information is based has not been independently verified. Nothing in this presentation constitutes tax or business advice and does not constitute a substitute consulting appropriate advisors in these aspects. Every potential investor should seek advice and guidance in connection with potential investments, including tax advice is given such investor tax status.

ALL TIME RECORD QUARTER Q1 2024 HIGHLIGHTS

• Revenue: 14.8 million, an 18% increase
• Accelerated supplements sales growth of 35%
• Adjusted EBITDA: \$2.4 million, a 19% increase
• Record orders' backlog of \$17 million
• Management changes

SALES AND ADJUSTED EBITDA Q1 2024 – BACK TO ACCELERATED GROWTH

USD Millions

STRATEGY EXECUTION SHOWS RESULTS – RECORD BACKLOG

• A strong increase in year-over-year customers' orders backlog of dietary supplements

OUR TRANSFORMATIONAL PIVOTS

How did we do?

TopGum 2024 7

CONFIDENTIAL

CONFECTIONERY SUPPLEMENTS

USD Millions

CONFECTIONERY SUPPLEMENTS

Sales development- a shift from confectionery to supplements USD Millions

14.8

TopGum 2024 9

\$0

\$2,000

\$4,000

\$6,000

\$8,000

\$10,000

\$12,000

\$14,000

\$16,000

GENERIC PRODUCTS TAILOR MADE How did we do?

4.3

USD thousand

0.8

^X 5

Proprietary

LOCAL INTERNATIONAL Expanding Our Global Reach

11

TOPGUM 4 STRATEGIC PILLARS

Pushing the edge of supplement gummies with improved functionality and better organoleptic qualities via propriety technology.

End-to-end solution

A to Z services of full turnkey solutions of supplement gummies to premium brands and strategic international CPGs.

Innovation leader Strategic partnerships

Strategic partnerships with market leaders to unlock higher value, focusing on niche markets with lower competition and clear competitive edge.

Increasing capacity

Supporting growing demand by tripling the production capacity in a new pharma grade facility, and by establishing warehouse and bottling facility in the US.

Highest standards of nutraceuticals in the industry INNOVATIVE DELIVERY SYSTEM

Differentiated Matrix

GUMMICEUTICALS Truly sugar-free/No-added sugar | Prebiotic effect Organic (fiber or sugar based) | Unique fibers matrix

Organoleptic Experience

Flavor | Color | Texture | Odor | Shape High-resistance melting point Clean label ingredients

Highest dosage per one gummy without affecting the flavor Awarded winning products

High Dosage Improved Functionality

Micro-encapsulation Masks flavors | Slow-release | Improves stability | Targeted release Enables new active ingredients | Preserves potency

Highest standards of nutraceuticals in the industry TOPGUM PROPRIETARY MATRIX

200 products in development

GUMMICEUTICALS

Truly sugar-free / No added sugar More than 60% of prebiotic dietary fiber

Sugar-free / No-added sugar No alcohol sugars No sweeteners Prebiotic effect

SUGAR-BASED

Gelatin or Pectin base More than 60% Sugar

SUGAR-FREE

Gelatin or Pectin base Artificial Sweeteners/Sugar alcohol (Maltitol)

Sugar-free / No-added sugar No alcohol sugars No sweeteners Prebiotic effect

HIGH DOSAGE

Mag 100+

*Available also in higher dosages: 100 mg / 150 mg / 200 mg and more

Highest dosage of Magnesium without any sandy texture and no metallic flavor!

Highest dosage of Vitamin C in a gummy ever, with a delicious taste.

T H E I R O N G U M M Y B Y T O P G U M

Highest dosage sugar-free Iron gummies .Fiber-based, which balances the iron and helps prevent constipation.

UNIQUE ORGANIC MATRIX Innovative line of organic gummies – Sugar free*

• Crafted with a unique and proprietary organic gummy matrix sugar free.
• A gummy line customizable to a wide range of formulas and delicious flavors.
• This line contains only natural flavors and colors without any sugar alcohols, or sweeteners of any kind.
• New license supply agreement with the leading organic gummy brand in the US.

A variety of formulations, natural flavors & natural colors

GUMMICCINO – COFFEE LINE The energizing experience of coffee

An exclusive range of coffee gummies by TopGum.

A proprietary technology allows us to infuse gummies with the amount of caffeine found in one espresso shot.

Won 2 nd place for the Best Tasting ESPRESSO CAPPUCCINO MOCHA Functional Food competition at

FOR COFFEE LOVERS ON THE GO

CAFFEINE DOSAGE (40 mg) 1 gummy = 1 espresso shot

MICROENCAPSULATION Proprietary technology using unique formulas and know-how

TopGum 2024 18

TopGum is building an advanced state-of the art, in-house microencapsulation facility

END TO END TECHNOLOGICAL SOLUTION TopGum is positioned as one of the leading CDMO* in the industry

IN-HOUSE PACKAGING AND BOTTLING Bottling – Growth Engine

• One stop shop from production to final product, we deliver full value to our customers
• In March 2022, a new bottling line became operational
• In the US we are currently subcontracting our bottling to a 3 rd party

~33%

of end-product price is bottling & labeling

Maximum customization, shape, size, color, material, caps, seals, labels.

TOPGUM'S BLUE CHIP CUSTOMER BASE CONTINUES TO EXPAND

21

NEW STATE-OF-THE-ART FACILITY UNDER CONSTRUCTION The construction of the new factory is at an advanced stage

• Most of the equipment, systems, and main infrastructure have been installed
• As a result of the war the first production line has been postponed and is currently set to become operative by the end of 2024
• The company is exploring options for the purchase or establishment of a manufacturing, bottling and logistics center in the USA
• The company is developing in-house QA and analytical lab capabilities following the acquisition of PharmItBe

P&L

P&L
USD thousands	Q 1 2023	% of sales	Q 1 2024	% of sales	YOY Change (%)
Revenues	12,487		14,760		18.2%
Cost of sales	8,156	65.3%	9,699	65.7%	18.9%
Gross profit	4,331	34.7%	5,061	34.3%	16.9%
R&D	682	5.5%	723	4.9%	6.0%
S&M	955	7.6%	1,195	8.1%	25.2%
G&A	1,853	14.8%	1,809	12.3%	(2.4%)
Operating profits	841	6.7%	1,334	9.0%	58.6%
Finance expenses (Incomes), net	212	1.7%	(194)	(1.3%)	(191.6%)
Profits before tax	629	5.0%	1,528	10.4%	142.8%
Tax expenses	162	1.3%	236	1.6%	45.0%
Net profits	467	3.7%	1,292	8.8%	176.6%
EBITDA	1,327	10.6%	1,912	13.0%	44.1%
Adjusted Ebitda	2,011	16.1%	2,397	16.2%	19.2%

Non-GAAP EBITDA excludes one-time expenses from ESOP grants and bonuses to employees regarding IPO / Equity transactions

BALANCE SHEET

USD thousands

	March 31, 2023	March 31, 2024
Assets
Currnet assets	31,124	48,649
Non-current assets	41,225	60,265
Total assets	72,349	108,914
Liabillities and equity
Current liabillities	20,695	16,223
Non-current liabillities	6,104	24,295
Equity	45,550	68,396
Total liabillities and equity	72,349	108,914

Thank you

TopGum 2024 25